GDTCNasdaq

CytoMed Therapeutics Ltd

Healthcare·Healthcare·Singapore, Singapore

CytoMed Therapeutics Ltd (GDTC): ~2 mo cash runway. Updated within the last hour.

5.2/10

BioSniper Score

2-factor signal · derived from public data

Cash Runway0.6

2.1 months

Financial Health9.8

D/E 0.17 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline BreadthN/A

N/A

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CytoMed Therapeutics Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$13.6M

Cash

$1.6M

Quarterly Burn

$2.9M

Runway

2.1 mo

Revenue

$252K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

2

Total value held

$10K

HolderSharesValue
xtx topco ltd10,136$10K
osaic holdings, inc.21$21

Frequently asked questions

What is CytoMed Therapeutics Ltd's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CytoMed Therapeutics Ltd has approximately 2.1 months of cash runway.

What is CytoMed Therapeutics Ltd's market capitalization?

CytoMed Therapeutics Ltd's market capitalization is approximately $13.6M.

Get the full picture on CytoMed Therapeutics Ltd

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.